Study guide
16.1 Therapeutic Apheresis
Specialist in Blood Banking, SBB ASCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility Routes & Credential Maintenance 1.3 Study Strategy for SBB
2 Donors & Collection
2.1 Donor Qualification 2.2 Collection Methods & Adverse Reactions 2.3 Special Donations
3 Processing, Storage & Component QC
3.1 Processing, Testing & Labeling 3.2 Storage, Transport & Expiration 3.3 Blood Component Quality Control
4 Red Cell & Modified Components
4.1 Whole Blood & Red Blood Cells 4.2 Leukocyte-Reduced, Washed, Frozen & Rejuvenated RBCs 4.3 Irradiated Components 4.4 Granulocytes
5 Platelets, Plasma & Cellular Products
5.1 Platelets 5.2 Plasma & Cryoprecipitated AHF 5.3 Apheresis Products & Fractionation Products 5.4 Hematopoietic Progenitors
6 Genetics, ABO & Rh
6.1 Blood Group Genetics & Molecular Inheritance 6.2 ABO & Lewis Systems 6.3 Rh System 6.4 MNS, P1PK/Globoside & Ii
7 Other Blood Groups & Role in Transfusion
7.1 Kell, Kidd, Duffy & Lutheran 7.2 Other Systems & High/Low-Prevalence Antigens 7.3 HLA, Platelet-Specific & Granulocyte Antigens 7.4 Immunogenicity & Antigen Prevalence
8 Immunology Foundations
8.1 Immune Response 8.2 Immunoglobulins 8.3 Antigen-Antibody Interactions 8.4 Complement
9 Physiology, Hemostasis & HDFN
9.1 Physiology of Blood 9.2 Hemostasis and Coagulation 9.3 HDFN Pathophysiology & Detection 9.4 HDFN Treatment & Prevention
10 Cytopenias & Transplantation
10.1 Immune & Nonimmune Anemia 10.2 Thrombocytopenia & Neutropenia 10.3 Solid Organ Transplantation Support 10.4 Hematopoietic Progenitor Cell Transplantation
11 Routine Serologic Testing
11.1 Blood Grouping Tests 11.2 Antibody Detection & Crossmatch 11.3 Antibody Identification & Clinical Significance 11.4 Direct Antiglobulin Testing & Reagents
12 Special Serologic Methods
12.1 Enzymes, Enhancement Media & Lectins 12.2 Adsorptions, Elutions & Titrations 12.3 Cell Separations, Neutralization & Thiol Reagents 12.4 Chloroquine Diphosphate & EDTA-Glycine Acid
13 Molecular Platforms & Serologic QA
13.1 Molecular Blood Group Techniques 13.2 ELISA, Immunofluorescence, Solid Phase & Column Agglutination 13.3 Serologic Quality Assurance
14 Indications, Component Therapy & PBM
14.1 Indications for Transfusion 14.2 Component Therapy 14.3 Blood Administration & Patient Blood Management
15 Adverse Effects of Transfusion
15.1 Immunologic Transfusion Reactions 15.2 Nonimmunologic Reactions 15.3 Transfusion-Transmitted Diseases
16 Apheresis & Extracorporeal Circulation
16.1 Therapeutic Apheresis 16.2 Extracorporeal Circulation
17 Quality, Safety, Math & Instrumentation
17.1 Quality Assessment & Troubleshooting 17.2 Laboratory Safety 17.3 Laboratory Mathematics 17.4 Instrumentation
18 Laboratory Administration (SBB Only)
18.1 Financial Management 18.2 Operations & Information Technology 18.3 Personnel, Education & Training 18.4 Quality Management, Risk & Tissue Management
16.1 Therapeutic Apheresis
Key Takeaways Explain This Topic AI
Therapeutic plasma exchange (TPE) removes plasma and replaces it with albumin, FFP, or a combination, chosen by the disease being treated.
ASFA grades apheresis indications from Category I (accepted first-line therapy) to Category IV (evidence shows harm or no benefit), and the category is the highest-yield fact for each disease.
A single one-plasma-volume exchange removes roughly 63% of an intravascular substance; most protocols exchange 1-1.5 plasma volumes per session because returns diminish sharply beyond that.
FFP replacement is mandatory in TTP because it restores ADAMTS13, the von Willebrand factor-cleaving protease that TTP patients lack.
Citrate anticoagulant chelates ionized calcium, making citrate-induced hypocalcemia (perioral tingling, tetany, arrhythmia) the most common apheresis-specific adverse reaction.
Last updated: July 2026
16.1 Therapeutic Apheresis
ASCP content outline domain V.D moves beyond the routine hemapheresis basics tested on the generalist MLS/MLT exams into the specialist-level decision-making an SBB is expected to own: which diseases genuinely need apheresis, which replacement fluid a given disease requires, and how to recognize and manage citrate toxicity. This section builds that specialist layer.
Apheresis Mechanics: Centrifugation vs. Filtration
Therapeutic apheresis separates whole blood into components and removes a target component while returning the remainder, plus a replacement fluid, to the patient. Most U.S. instruments use continuous-flow centrifugation : blood spins in a disposable channel so components stratify by density (plasma on top, then platelets, the white cell/buffy-coat layer, and red cells at the bottom), allowing continuous separation while blood cycles between the patient and the machine. Membrane (filtration) plasmapheresis passes plasma through a porous membrane under a pressure gradient instead of spinning it; it is used less often in the U.S. but underlies double filtration plasmapheresis , a secondary filtration step that selectively removes large pathologic proteins (LDL, IgM) while sparing albumin.
Two Broad Categories: Plasma Exchange and Cytapheresis
Therapeutic Plasma Exchange (TPE) removes plasma, and with it the pathologic substances dissolved in it - autoantibodies, immune complexes, paraproteins, toxins, lipoproteins - and replaces the removed volume with a substitute fluid.
Cytapheresis removes a cellular component instead of plasma:
Leukapheresis removes white cells; therapeutic use targets extreme hyperleukocytosis with leukostasis (blast crisis), while the same technology also collects peripheral blood stem cells or granulocytes for transfusion.
Plateletpheresis (thrombocytapheresis) removes platelets; therapeutic use is rare, reserved for extreme thrombocytosis causing thrombotic or hemorrhagic symptoms (essential thrombocythemia crisis).
Erythrocytapheresis (RBC exchange) removes and replaces red cells; its main therapeutic use is sickle cell disease (acute stroke, acute chest syndrome, pre-operative prophylaxis), lowering %HbS while avoiding the iron overload and viscosity problems of simple transfusion.
Extracorporeal photopheresis (ECP) collects a mononuclear cell fraction, exposes it ex vivo to a photoactive drug (8-methoxypsoralen) and UVA light, then reinfuses the treated cells; it is used for cutaneous T-cell lymphoma, graft-versus-host disease, and solid-organ transplant rejection.
Exchange Volume and Kinetics
Continuous-flow TPE follows first-order (exponential) removal kinetics: removing one plasma volume (1 PV) clears about 63% of an intravascular substance, 1.5 PV clears about 78-80% , and 2 PV clears about 86% . Because the return per additional volume shrinks quickly past 1.5 PV, most protocols exchange 1-1.5 PV per session, typically daily or every other day depending on disease severity. Patient plasma volume is estimated as total blood volume (roughly 70 mL/kg in adults) multiplied by (1 minus hematocrit).
ASFA Categories: Grading the Evidence
The American Society for Apheresis (ASFA) publishes a periodically updated set of disease fact sheets that grade conditions by how strongly the evidence supports apheresis. Conceptually, the four categories are:
Category Meaning Representative diseases
I Accepted as first-line therapy, alone or combined with other treatment TTP, Guillain-Barre syndrome, myasthenic crisis, hyperviscosity syndrome, anti-GBM disease with pulmonary hemorrhage, ANCA-associated RPGN with dialysis dependence
II Accepted as second-line therapy Chronic inflammatory demyelinating polyneuropathy, ABO-incompatible solid-organ transplant desensitization
III Optimum role not established; decision individualized ANCA vasculitis without severe renal failure, sepsis with multi-organ failure
IV Published evidence shows apheresis is ineffective or harmful; use requires case-by-case (e.g., IRB) oversight Rheumatoid arthritis, psoriasis
Each disease fact sheet also carries a recommendation grade (1A-2C) , mirroring GRADE methodology, that separately scores the strength of the recommendation and the quality of the supporting evidence. On the SBB exam, the numbered category (I-IV) is tested far more often than the letter/number grade, because it answers the practical question a blood bank physician or SBB has to answer: is apheresis standard of care for this patient, or is it experimental?